OLMA OLEMA PHARMACEUTICALS INC US FDA Inspections 8-K Filing 2024 - FDA Clearance Olema Pharmaceuticals announced FDA clearance for its OP-3136 drug and updated results from a clinical study of palazestrant, showing promising efficacy in breast cancer treatment with a 6-month progression-free survival rate of 73%.Get access to all SEC 8-K filings of the OLEMA PHARMACEUTICALS INC